Skip to main content


    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

  • Published:

Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial



Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disease progression. Hence, identification of alternative treatments for patients is important. The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. Because a considerable proportion of ADPKD patients presenting with chronic kidney disease (CKD) stages III–IV are diagnosed with the spleen, kidney deficiency, and blood stasis syndrome according to the diagnostic criteria of traditional Chinese medicine (TCM), we hypothesize that YNF may be a complementary drug for ADPKD patients with the corresponding syndrome. Therefore, we have designed a strict clinical trial to evaluate the safety and efficacy of YNF for ADPKD patients with CKD stages III–IV exhibiting the TCM syndrome of spleen, kidney deficiency, and blood stasis.


This is a multi-center prospective double-blind randomized controlled trial. The total target sample size is planned to be 72 participants, with a balanced treatment allocation (1:1). The experimental intervention will be YNF plus conventional therapy and the control intervention will be a placebo plus conventional therapy for 24 weeks. An additional 24 weeks of follow-up will be conducted after treatment completion. The primary outcome will be the estimated glomerular filtration rate (eGFR). Changes in total kidney volume (TKV), serum creatinine (Scr), blood urea nitrogen (BUN), TCM symptoms, and pain will be the secondary outcomes. Adverse events (AEs) will be monitored throughout the trial.


This study will be the first placebo-controlled randomized controlled trial to assess whether YNF plus conventional therapy has a beneficial effect on eGFR, TKV, Scr, and BUN, and whether it can alleviate TCM clinical symptoms, reduce ADPKD-related pain, and reduce the frequency of AEs for ADPKD patients with CKD stages III–IV with the spleen, kidney deficiency, and blood stasis syndrome. The results of this trial may provide an evidence-based recommendation for clinicians.

Trial registration

Chinese Clinical Trials Register, ChiCTR-INR-16009914. Registered on 18 November 2016.


Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. The incidence of ADPKD worldwide is about 1 in 1000 to 1 in 400 [1]. It is the fourth most common cause of end-stage renal disease (ESRD) requiring renal replacement therapy. It is characterized by accelerated cyst growth resulting in increased total kidney volume (TKV) and renal dysfunction [2, 3], and it affects more than 1.5 million people in China [4] and up to 12 million individuals worldwide [5]. ADPKD is a heterogeneous disorder with two genes identified: PKD1 and PKD2 [6]. The prevalence of autosomal recessive polycystic kidney disease is less common than ADPKD, but together with nephrophthaisis is the leading cause of ESRD in childhood [7].

Currently, there are few management options for controlling these diseases. Patients with ADPKD and renal failure are most commonly treated with hemodialysis. The treatment includes non-specific measures that are applicable to all ESRD patients, such as strict blood pressure control, dietary protein restriction, a low salt diet, and statins, which may prevent progression of the disease and reduce cardiovascular mortality [8]. Useful drugs in the management of ADPKD include small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, vasopressin V2-receptor (V2R) antagonists, and somatostatin analogues [9]. However, there are a number of limitations with those medications. V2R antagonists and newer agents inhibit pathological pathways in cyst formation. Several preclinical and clinical studies on the V2R antagonist tolvaptan reported evidence of its usefulness in ameliorating the decline of renal function over 1 year in later-stage ADPKD [10]. Since some questions and problems remain (e.g., hepatotoxicity, polyuria, polydipsia, no data on quality of life, and cost-effectiveness) [11], the use of tolvaptan requires careful consideration and balancing of benefits and risks [12]. The lack of specific treatment options for ADPKD makes it difficult for physicians and researchers working in nephrology.

Chinese herbal medicine has been used in the treatment of diseases for thousands of years in China. It is well known that traditional Chinese medicine (TCM) cures ailments based on syndrome differentiation, which is the main characteristic and therapeutic rule of TCM. Clinical information is gathered using the four main diagnostic TCM procedures (observation, listening, interrogation, and pulse-taking) and diagnosis follows TCM criteria. With our many years of clinical practice in the management of ADPKD, we have found that the main pathogenesis of ADPKD is spleen and kidney deficiency (soreness and weakness of the waist and knees, fatigue, cold or numbness of limbs, mental listlessness, lower limb edema, frequent night urination, and sunken pulse) combined with blood stasis (abdominal mass, pain or tingling in the back, subcutaneous petechia, squamous and dry skin, chest tightness, dark purple or dull red tongue with white fur, and strong astringent pulse). The clinical terms for these symptoms are those used in TCM for diagnosis and treatment. The national standard in China for this syndrome was published in February 1997 [13] and was verified by our previous work [14].

The yinang formulation (YNF) is derived from a Chinese patent drug originally designated for the clinical treatment of ADPKD patients diagnosed with the spleen, kidney deficiency, and blood stasis syndrome [14]. However, it is not clear whether YNF is effective for ADPKD patients with chronic kidney disease (CKD) stages III–IV. We hypothesized that for patients with ADPKD, YNF could improve the estimated glomerular filtration rate (eGFR), improve serum creatinine (Scr) levels, reduce TKV, reduce the blood pressure, improve symptoms and signs of CKD, reduce ADPKD-related pain, and reduce the number of adverse events (AEs). Thus, a multi-center prospective double-blind placebo-controlled randomized clinical trial was designed to evaluate the safety and efficacy of YNF for CKD stages III–IV in ADPKD patients.

Aim of the trial

This clinical trial aims to disprove the null hypothesis that YNF granules in an oral dose of 36 g taken twice daily compared to a placebo does not improve the renal function of ADPKD patients at CKD stages III–IV with the spleen, kidney deficiency, and blood stasis syndrome.


Trial design

This is a multi-center randomized double-blind placebo-controlled clinical trial lasting 24 weeks. An additional 24 weeks of follow-up will be conducted after treatment completion. The design of the trial follows a strict scientific clinical research methodology and complies with principles of the Declaration of Helsinki and the guidelines for good clinical practice (Fig. 1).

Fig. 1

Patient flow in the YNF study for the intention-to-treat analysis. ADPKD autosomal dominant polycystic kidney disease, BID twice daily, TCM traditional Chinese medicine, TKV total kidney volume, YNF yinang formulation

Sample size calculation

The sample size was based on the primary outcome of a change in baseline eGFR. To determine the sample size, we reviewed unpublished data for eGFR changes for 22 ADPKD outpatients at CKD stages III–IV. The mean value of eGFR was 26.71 mL/min/1.73 m2, and the standard deviation was 8.53 mL/min/1.73 m2. It was assumed that eGFR for the YNF group would be significantly higher than for the control group by more than 6 mL/min/1.73 m2 after 24 weeks. If α = 0.05 and the test efficacy 1 – β = 0.80, then the sample size

$$ {n}_1=\kern0.5em \kappa {n}_2 $$


$$ {n}_2=\frac{\left({\mathrm{Z}}_{\alpha /2}+{\mathrm{Z}}_{\beta}\right){}^2\kern0.5em \sigma {}^2\kern0.5em \left(1\kern0.5em +\kern0.5em 1/\kappa \right)}{\varepsilon^2}. $$

Thus, n1 = 64, with 32 in each treatment group. Considering a 10% dropout rate, the planned sample size for randomization was increased to 72. Participants will be randomly assigned in a ratio of 1:1. Each of the three participating hospitals will recruit 24 patients, 12 in the experimental group and 12 in the control group.

Study setting and recruitment

This study will recruit 24 outpatients at each of three trial sites in Shanghai in mainland China: (1) Shuguang Hospital affiliated to Shanghai University of TCM, (2) Shanghai Changzheng Hospital affiliated to the Second Military Medical University, and (3) Shanghai Municipal Hospital affiliated to Shanghai University of TCM. Advertisements to encourage people to enroll in the clinical trial will be posted on the study's web page.


The study plans to enroll 72 patients diagnosed with ADPKD at CKD stages III–IV and with the spleen, kidney deficiency, and blood stasis syndrome. To be enrolled in the trial, potential participants must satisfy the inclusion and exclusion criteria listed below.

Diagnostic criteria for ADPKD

Participants are diagnosed with ADPKD based on a known family history, imaging features, or genetic testing. No distinction will be made between those with mutations of PKD1 or PKD2. For patients with ADPKD, eGFR is within the range 15 to 60 ml/min/1.73 m2. Patients have abnormal laboratory tests, and loss of renal structure and endocrine function for more than 3 months. It is an irreversible and chronic progressive disease [15].

Diagnostic criteria for TCM syndrome differentiation

According to the Guidelines for Clinical Research of Chinese Medicine (New Drug) [16], a patient has to present with at least two of the primary symptoms and more than two of the secondary symptoms listed below to be diagnosed with the spleen, kidney deficiency and blood stasis syndrome.

Primary signs and symptoms:

  • abdominal mass

  • soreness and weakness of the waist and knees

  • pain or tingling in the back

  • fatigue

  • cold or numbness of limbs

Secondary symptoms:

  • mental listlessness

  • lower limb edema

  • subcutaneous petechia

  • squamous and dry skin

  • chest tightness

  • frequent night urination

  • dark purple or dull red tongue with white fur

  • weak, sunken, or strong astringent pulse

Inclusion criteria

  • adult subjects with a diagnosis of ADPKD as stated above and with a TCM diagnosis of the spleen, kidney deficiency, and blood stasis syndrome

  • aged 18–75 years

  • 15 mL/min/1.73 m2 ≤ eGFR < 60 mL/min/1.73 m2

  • not receiving renal replacement therapy

  • not suffering from chronic hepatitis, hepatic dysfunction, cardiovascular diseases, or any other life-threatening conditions

  • negative urine or serum pregnancy test within 24 h prior to administration of YNF and agrees to use contraception throughout the study and for 6 months after

Exclusion criteria

  • ADPKD is accompanied by proteinuria (> 1 g/d)

  • diabetic patients

  • unable to or do not consent to participate in the study

  • suffering from chronic hepatitis, drug-induced hepatic dysfunction, or another type of hepatic dysfunction

  • recent participation in another clinical trial

  • probable, highly likely, or definite allergy to any of the ingredients in the test drug

  • contraindications to magnetic resonance imaging (MRI)

  • taking medications likely to affect ADPKD outcomes

Participant withdrawal criteria

Participants will be withdrawn from the study if

  • They violate any of the key inclusion or exclusion criteria.

  • They refuse to continue to participate or withdraw their consent.

  • They undergo a serious adverse event (SAE).

  • They have unbearable ADPKD-related pain and choose cyst decompression as a surgical intervention during the study.

  • The principal investigator or co-investigators judge that they need to be withdrawn from the study.

  • A hepatocellular injury is detected, indicated by alanine transaminase (ALT) or aspartate transaminase (AST) levels > 3 × ULN and total bilirubin > 2 × ULN, where ULN is the upper limit of normal.

  • They have hematuria during treatment.


The central randomization list was generated by an independent statistician using SPSS (version 24.0, IBM, NY, USA). Altogether, 36 patients will be assigned to the intervention group and to the control group using a balanced block randomization with 6 blocks. We will randomly select blocks of size 4. Telephone-based randomization will be performed at each coordinating center by an independent physician who is not engaged in recruitment, treatment, or assessment. Participants will be randomly assigned in each site to the YNF group and the placebo group in a ratio of 1:1. After screening, if the patient agrees to participate and voluntarily signs the informed consent form (Additional file 2), the independent physician in each trial site will sequentially assign a random number to them.


This clinical trial will be double blind. The physicians, investigators, co-investigators, clinical trial pharmacists, and patients are all blinded to the allocation, except for the independent statistician who generated the randomization.

The placebo granules will be indistinguishable from the YNF granules in shape, size, color, and packaging. Thus, all clinicians and participants will be masked. The packaging will be labeled with sequential random numbers in advance by a pharmaceutical company according to the randomization list sent by the independent statistician. The independent statistician will go to the pharmaceutical company to check the packaging when the drugs are being labeled. At each trial site, based on their allocation, a patient will be given the package of YNF or the placebo with the lowest number by a designated clinical trial pharmacist who is not involved with the study and is blind to the allocation.

Unblinding will be done according to the standard operating procedure of the contract research organization [17]. For each subject, an emergency plan and their treatment plan will be sealed in an opaque envelope, to allow unblinding if there is a serious adverse reaction and possibly to ensure the correct treatment method was administered. If an emergency occurs, the principal investigator will ask an independent physician to unblind the patient and the incident will be reported to the independent safety monitoring board.


According to the guideline for the management of ADPKD [18], drugs used in the treatment of hypertension, hematuria, concurrent infections, and other diseases will be used reasonably for patients in both groups as basic therapy, except for Chinese patent drugs. The name and dosage of any drug administered will be recorded. In addition to their standardized Western medicine, participants randomized to the treatment group will be administered YNF as an oral dose of 36 g twice daily 1 h after breakfast and dinner for 24 weeks. Those in the control group will receive the placebo as an oral dose of 36 g twice daily 1 h after breakfast and dinner for 24 weeks. Both groups will receive behavioral intervention and health education, such as diet instructions. All co-investigators and patients will be educated about drug administration methods.

The YNF granules (10% YNF) and the placebo granules will be manufactured by Jiangsu Tianyin Pharmaceutical Co. Ltd. (1 Xin Sheng Street, Jiangyin High-tech Zone, Jiangsu) according to good manufacturing practice. The composition and action of each herb are summarized in Table 1.

Table 1 Composition and action of yinang formulation in Chinese herbal medicine

Measurement items and time points of data collection

Relevant examinations will be performed to collect patient data at 24 weeks before baseline, at baseline, every 4 weeks from 4 to 24 weeks during treatment, and an additional follow-up evaluation will be performed at visit 9 (48 weeks). General information collected will include name, age, gender, ID number, date of birth, home address, contact information, history of present illness, past medical history, family history, personal life history, menstrual history, marital history, allergy history, social history, physical examination results, and laboratory examination results.

There is evidence that age-related TKV can reflect the progress of ADPKD. An MRI scan can accurately measure renal blood flow and evaluate renal cyst compression, which is associated with pain, hypertension, hematuria, albuminuria, and loss of renal function. TKV combined with age and renal function can be used to evaluate the risk of progress to ESRD [19]. The T2 shortening imaging technique of MRI with no radiation damage, no use of gadolinium as a contrast agent, and no risk of nephrogenic systemic fibrosis is recommended and will be used in this study [20]. The outcome is the percentage semi-annual change in TKV measured by MRI, which will be performed at visit 1, visit 2 (24 weeks after visit 1), and visit 8 (24 weeks after visit 2) to observe the growth in kidney volume before and after the intervention.

Items to be measured and the time points of data collection are listed in Table 2.

Table 2 SPIRIT table: Measurement items and time points of data capture


The primary outcome of this trial will be the eGFR using the CKD Epidemiology Collaboration formula [21]. Secondary outcomes include changes in TKV, Scr, blood urea nitrogen (BUN), TCM symptoms, and pain. A composite outcome looks at the incidence rates of all possible safety events between two groups. AEs will be monitored throughout the trial and several biological indicators (blood and urine tests, electrocardiograms, and liver function test) will also be closely watched.

Measurement scale for TCM symptoms

The measurement scale for TCM symptoms recommended by the Guidelines for Clinical Research of Chinese Medicine (New Drug) [16] will be used for ease of assessment. Each of the primary symptoms necessary for the diagnosis of the spleen, kidney deficiency, and blood stasis syndrome will be scored 0, 2, 4, or 6, while secondary symptoms will be scored 0, 1, 2, or 3. The scores will be summed to yield a total score for each set of symptoms for each patient. The total primary symptom score cannot exceed 18 and the total score for secondary symptoms cannot exceed 33 for a patient. The two totals will be added together and any change in this score will be calculated for each patient and used to calculate an efficacy indicator (EI) for the evaluation of treatment efficacy:

$$ \mathrm{EI}=\left(\mathrm{Total}\ \mathrm{symptom}\ \mathrm{score}\ \mathrm{at}\ \mathrm{baseline}-\mathrm{Total}\ \mathrm{symptom}\ \mathrm{score}\ \mathrm{post}-\mathrm{treatment}\right)/\mathrm{Total}\ \mathrm{symptom}\ \mathrm{score}\ \mathrm{at}\ \mathrm{baseline}\times \kern0.37em 100\% $$

The degree of symptom improvement will be presented in four categories ranging from full recovery (EI ≥ 90%), good recovery (90% > EI ≥ 70%), and modest recovery (70% > EI ≥ 30%) to no recovery (EI < 30%).

Pain evaluation scale

Pain is the most common complaint of patients with ADPKD. Causes of pain are multiple but include cyst enlargement, cyst rupture, and secondary infection [22]. Good remission of ADPKD-related pain (low back pain, abdominal pain, headache, chest pain, and leg pain) can alter a patient’s quality of life. The visual analog scale (VAS) is a 10-cm horizontal line anchored by two extremes. It will be used to measure ADPKD-related pain [23]. Patients will be instructed to complete a pain diary for the day at each visit. According to this scale, 0 cm means no pain or no discomfort, whereas the 10-cm end indicates the worst pain or extreme discomfort. The baseline will be the VAS score at visit 2. The difference in pre- and post-treatment VAS scores will be a secondary outcome. At the final visit, patients will complete a global assessment of their overall responses after the trial. The global assessment [24] is a five-point scale: 0 = worsened, 1 = no change, 2 = slightly improved, 3 = improved, and 4 = significantly improved.

Statistical analysis

A formal and detailed statistical analysis plan will be formulated before the database is locked. The baseline characteristics of both groups, such as gender, age, and smoking status, will be compared by either a χ2 test or Student’s t-test. Continuous variables will be presented as means ± standard deviations or medians, and differences in such variables will be analyzed using an independent t-test or the Wilcoxon signed-rank test. A repeated measurement of variance analysis model of these outcomes will be built.

The difference in eGFR will be tested using two-way ANOVA with repeated measures. Categorical variables will be expressed as numbers and percentages, and differences in such variables will be calculated and compared using a χ2 test and Fisher’s exact test. All statistical tests will be two-sided, and the level of significance will be set to P < 0.05. Multiple imputation will be used to handle missing data. All patients enrolled will be included in the primary analysis in accordance with the intention-to-treat principle. The statistical analysis will be performed in a blind manner by an independent statistician using SPSS (version 24.0, IBM, NY, USA). No additional analyses or an interim analysis are scheduled.

Data and safety monitoring

An independent data and safety monitoring board comprising cardiovascular surgeons, anesthesiologists, and statisticians will oversee all aspects of the study. The board will meet twice during the trial to monitor safety. It will make recommendations on study progress and performance, identify any major adverse outcomes or AEs due to the therapy, and give advice regarding whether the study should continue or if there should be a protocol change.

In this study, AEs are defined as any negative or unintended clinical manifestations that occur after the start of the study, regardless of medication. Any unexpected symptoms and signs, feelings of discomfort, or occurrence of AEs in patients during the trial will be recorded using medical diagnostic terminology on a case report form with detailed symptoms, time of occurrence, duration, severity, possible causal relationships, actions taken, results, and other relevant information. If an AE occurs, the patient will be monitored until their AE disappears. A follow-up investigation will be conducted, and the results will be recorded in case the intervention is halted due to the AE. The chief principal investigator (JDG) is responsible for reporting all AEs to the board and the regulatory authorities within 24 h.

The following are possible safety events relating to the intervention:

  • decrease of eGFR by ≥50%

  • Scr doubled since the last blood test

  • progression to CKD stage V

  • serious cardiovascular or cerebrovascular events

  • heart rate < 40 bpm

  • any unexpected event that the investigator believes could be attributed to the intervention

SAEs include any of the following:

  • fatal or life-threatening complications

  • death or persistent or significant disability

  • hospitalization or significant medical intervention to prevent a serious outcome

  • any events that investigators examine are significant hazards or harm to the participants

Stopping rules for the trial:

  • If an insufficient number of patients is enrolled.

  • If the allocation codes are leaked during the trial or if more than 20% of the envelopes with emergency plans are opened, which would mean that the blinding has been nullified.

  • Occurrence of SAEs that are likely to be related to the intervention drugs in the trial, which may indicate there are serious problems with the safety of the drug.

Data entry and quality control of data

Participant adherence to the protocol will be monitored by interviews at study check-up visits, which will promote retention and completion of follow-up assessments.

After verification of the content of the written case report forms, the data will be input independently into a database by two full-time research staff. To maintain data quality, all investigators will receive centralized training before the trial begins. Personal information (such as name, age, gender, ID number, date of birth, home address, contact information) will be kept in a locked storage unit according to standard guidelines. The quality control of the data will be assessed by the data and safety monitoring board three times at each trial site. The board will check that study procedures have been followed correctly according to the approved protocol. They will compare the data in the database with the source documents to evaluate its accuracy, completeness, and authenticity. The data and safety monitoring board will meet when the first participant enrolls, when 50% of the participants have been recruited, and when the last participant enrolls.

Ethics approval

This study has been approved by the international review board of each participating hospital. The trial was registered with the Chinese Clinical Trials Register (ChiCTR-INR-16009914) on 11 November 2016 ( Only clinicians with relevant qualifications will act as principal investigators. Written informed consent for the collection and use of participant data and biological specimens will be obtained from individual participants or authorized surrogates prior to enrollment. Personal information about potential and enrolled participants will not be disclosed to any third party before, during, or after the trial.


There are few management options for ADPKD. In East Asia, Chinese herbal medicine is one of the most common treatments. In TCM, the spleen and kidneys govern the movement and transformation of qi and fluid and these organs cooperate with each other to participate in the metabolism of water. A functional disorder of the spleen or kidneys would lead to qi stagnation and blood stasis, resulting in abdominal mass and fatigue. Therefore, nourishing the kidneys and spleen and removing blood stasis is an important aspect of treatment.

YNF is an improved version of a herbal prescription based on the therapeutic work of the late TCM practitioner Pingdong Zheng, who enjoyed nationwide fame for treating patients with chronic renal failure [25]. Compared with the original patent prescription [14], YNF is better in two ways. First, pangolin powder, which is expensive, was substituted by spina gleditsiae. Second, TCM granules are used instead of TCM slices to ensure the quality requirements in term of drug concentration and effectiveness of the ingredients.

YNF is a combination of 17 herbal ingredients, which have a synergistic effect of nourishing the kidneys and spleen and alleviating blood stasis according to preclinical study evidence [14]. It is recommended for treating a variety of indications, including abdominal mass, soreness and weakness of the waist and knees, pain or tingling in the back, fatigue, cold or numbness of limbs, and mental listlessness. The potential mechanism of YNF in the treatment of ADPKD needs to be further explored. It has been reported that some of the herbs in YNF have pharmacological effects, such as inhibiting platelet and erythrocyte aggregation and improving the microcirculation [26, 27], relieving pain [28], anti-inflammation [29], anti-fibrous tissue proliferation [30, 31], anti-oxidant [32, 33], and anti-tumor [34] activities. Such activities may contribute (1) to the inhibition of cyst growth and cell proliferation, (2) to reducing the compression of the renal parenchyma, which is good for relieving ADPKD-related pain, and (3) to down-regulating Scr and BUN levels to improve renal function. Understanding which ingredients of YNF alleviate the symptoms of ADPKD requires further research. YNF has been used in clinical practice for several years and no safety concerns have been raised. The common adverse effects of YNF, such as diarrhea and increased urine output, appear to be mild and self-limited. The favorable safety profile of YNF increases its acceptability with the general population.

In view of the current evidence base, we have designed this placebo-controlled randomized controlled trial to test the efficacy and safety of YNF for ADPKD patients with CKD stages III–IV with the spleen, kidney deficiency, and blood stasis syndrome. This protocol complies with the SPIRIT 2013 [35] statement and SPIRIT 2013 explanation and elaboration [36], which cover scientific, ethical, and safety issues (Additional file 1). For patients with ADPKD, the findings of this study may help to improve their clinical symptoms and renal function, and slow cyst growth. We expect that this trial may provide preliminary evidence for the efficacy of YNF in treating ADPKD, which would be useful for researchers, practitioners, and patients.

There are some limitations to this study. First, considering the longer term, it was not feasible to measure the rates of more clinically important outcomes, such as renal replacement therapy or transplant. Second, this study is being performed in Shanghai, China, and it is uncertain whether the relative effects of YNF would be similar in other ethnic groups. Third, which ingredients in YNF contribute to the treatment effect needs further research and exploration.

Trial status

The research strategy and study protocol were developed between October 2017 and June 2019. From October 2018 to July 2019, patients were screened and TKV was measured by MRI 24 weeks before the baseline. The follow-up visits and data analysis will take place from July 2019 to December 2020.

Availability of data and materials

Does not apply.



Angiotensin-converting enzyme inhibitor


Autosomal dominant polycystic kidney disease


Adverse event


Serum albumin


Alanine aminotransaminase


Angiotensin receptor blocker


Aspartate aminotransaminase


Twice daily


Blood urea nitrogen


Chronic kidney disease


Estimated glomerular filtration rate


Efficacy indicator


End-stage renal disease


Human chorionic gonadotrophin




Magnetic resonance imaging


Polycystic kidney disease


Retinol-binding protein


Serious adverse event


Serum creatinine


Traditional Chinese medicine


Total kidney volume


Upper limit of normal


Vasopressin V2-receptor


Visual analog scale


Yinang formulation




Gamma glutamyl transpeptidase


  1. 1.

    Meijer E, Jong PE, Peters DJ, Gansevoort RT. Better understanding of ADPKD results in potential new treatment options:ready for the cure. J Nephrol. 2008;21(2):133–8.

  2. 2.

    Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–301.

  3. 3.

    Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens. 2012;21(2):189–94.

  4. 4.

    Dai B, Mei CL. Research on autosomal dominant polycystic kidney disease in China. Chin Med J (Engl). 2006;119:1915–24.

  5. 5.

    Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney Disease: improving global outcomes (KDIGO) controversies conference. Kid Int. 2015;88(1):17–27.

  6. 6.

    Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Cli J Am Soc Nephrol. 2008;3(4):1197.

  7. 7.

    Torres VE. Vasopressin antagonists in polycystic kidney disease. Kid Int. 2005;28(3):2405–18.

  8. 8.

    Lin R. Tolvaptan: a possible treatment for autosomal dominant polycystic kidney Disease. Ann Am Acad Pol Soc Sci. 2013;36(2):153–64.

  9. 9.

    Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):820–9.

  10. 10.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney Disease. N Engl J Med. 2017;377:1930–42.

  11. 11.

    Gross P, Schirutschke H, Paliege A. Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers? Neph Dia Tran. 2019;34:35–7.

  12. 12.

    Blair HA. Tolvaptan: a review in autosomal dominant polycystic kidney Disease. Drugs. 2019;79:303–13.

  13. 13.

    State Bureau of Technical Supervision. GB/T 16751.2–1997. Clinic terminology of traditional Chinese medical diagnosis and treatment—syndromes. Beijing: Standards Press of China. 1997;2(7):13.

  14. 14.

    Li RL, Du XR, Ding SY, Huang D, He LQ, Wang C, et al. Clinical observation of YNF on the treatment of ADPKD patients with spleen, kidney deficiency and blood stasis syndrome. Chin J Integr Tradit West Nephropathy. 2016;17(8):682–5.

  15. 15.

    Levin A, Stevens PE, Bilous RW, Coresh J, Francisco ALMD, Jong PED, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.

  16. 16.

    Zheng YY. Guidelines for clinical research of Chinese medicine (new drug). Beijing: Chinese Medicine and Science Publication House; 2002.

  17. 17.

    Sul JU, Kim MK, Leem J, Jo HG, Yoon SH, Kim J, et al. Efficacy and safety of gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-tang, Keishikajutsubuto, TJ-18) for knee pain in patients with degenerative knee osteoarthritis: a randomized, placebo-controlled, patient and assessor blinded clinical trial. Trials. 2019;20:140.

  18. 18.

    Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—a KDIGO consensus report. Kid Int. 2015;88(4):676–83.

  19. 19.

    Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479–86.

  20. 20.

    Dambreville S, Chapman AB, Torres VE, King BF, Wallin AK, Frakes DH, et al. Renal arterial blood flow measurement by breath-held MRI: accuracy in phantom scans and reproducibility in healthy subjects. Magn Reson Med. 2010;63:940–50.

  21. 21.

    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

  22. 22.

    Bajwa ZH, Sial KA, Malik AB, Steinman TI, et al. Pain patterns in patients with polycystic kidney disease. Kidney Int. 2004;66:1561–9.

  23. 23.

    Johnson EW. Visual analog scale (VAS). Am J Phys Med Rehabil. 2001;80:717.

  24. 24.

    Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of Otilonium bromide treatment in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):402–10.

  25. 25.

    Gao JD, Wang C, Hou WG. Zheng Pingdong’s experience in treating chronic renal failure. J Tradit Chi Med. 2008;6:498–525.

  26. 26.

    Liu AP, Hao G. Parallel randomized controlled study of thyroid adenoma casual treatment of endometriosis. J Pract Tradit Chin Int Med. 2014;5:46–7.

  27. 27.

    Zhu H, Liu X, Zhu TT, Wang XL, Qin KM, Pei K, et al. UHPLC-MS/MS method for the simultaneous quantitation of five anthraquinones and gallic acid in rat plasma after oral administration of prepared rhubarb decoction and its application to a pharmacokinetic study in normal and acute blood stasis rats. J Sep Sci. 2017;40:2382–9.

  28. 28.

    Dang CL, Xin XN. Influence of Rhizoma sparganii on hemorrheology of rabbits. J Henan Med Uni. 1996;03:31–2.

  29. 29.

    Chu X, Liu XJ, Qiu JM, Zeng XL, Bao HR, Shu J, et al. Environ Toxicol Pharmacol. 2016;48:76–84.

  30. 30.

    Gao JY, Yang X, Yin WP. From traditional usage to pharmacological evidence: a systematic mini-review of spina gleditsiae. Evid Based Complement Alternat Med. 2016;2016:3898957.

  31. 31.

    Liu MH, Huang XW, Xiao SH, Zhong L, Ren MP, Tian J. Effects of Extractive from Spina Gleditsiae (ESG) on Tumor Growth and Cytokines in Tumor-bearing Mice. Cancer Res Prevent Treat. 2009;36(05):365–7.

  32. 32.

    Hu W, Han W, Huang C, Wang MH, et al. Protective effect of the methanolic extract from Duchesnea indica against oxidative stress in vitro and in vivo. Environ Toxicol Pharmacol. 2011;31:42–50.

  33. 33.

    Arora R, Kumar R, Agarwal A, Reeta KH, Gupta YK. Comparison of three different extracts of Centella asiatica for anti-amnesic, antioxidant and anticholinergic activities: in vitro and in vivo study. Biomed Pharmacother. 2018;105:1344–52.

  34. 34.

    Wang C, Zhou X, Wang Y, Wei D, Deng C, Xu X, et al. The antitumor constituents from Hedyotis Diffusa Willd. Molecules. 2017;22(12):2101.

  35. 35.

    Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Internal Med. 2013;158(3):200–7.

  36. 36.

    Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

Download references


The authors gratefully thank all the trial pharmacists at each hospital: Dongdong Li (Shuguang Hospital affiliated to Shanghai University of TCM), Xiaoliu Wang (Shanghai Changzheng Hospital affiliated to the Second Military Medical University), and Zi Ye (Shanghai Municipal Hospital affiliated to Shanghai University of TCM). We gratefully acknowledge Hua Lv for assisting with the medical statistics and Dechao Xu for coordinating the study. We also thank Xiang Gao, Shenyan Liu, Xinzhi Zhang, Peng Wang, Zhili Li, Ming Wang, Xuelian Li, Yihao Wang, Zizheng Zhou, and Dongping Chen for their assistance with patient recruitment.


This work is supported by a Shenkang 3-year project “Specialized clinical disease five new transformation project” (grant 16CR3021A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

JG is an investigator responsible for participant identification and screening, and drafted the manuscript. YW participated in the design of the study and contributed to the development of the statistics referred to in the protocol. XG is a co-investigator responsible for participant recruitment and assessments, contributed to developing the protocol and reviewing the manuscript, will assist with the data analysis, and will assist with the organization of study visits and monitoring. YM contributed to developing the protocol and will assist with the data analysis. SY is a co-investigator responsible for participant recruitment and assessments, contributed to developing the protocol and reviewing the manuscript, and will assist with the organization of study visits and monitoring. JDG is the chief investigator and contributed to study conception, developing the protocol, and reviewing the manuscript. All authors read and approved the final manuscript.

Correspondence to Shengqiang Yu or Jiandong Gao.

Ethics declarations

Ethics approval and consent to participate

This study has been approved by the ethics committee of each participating hospital. The international review board of Shuguang Hospital affiliated to Shanghai University of TCM approved the original protocol of this study on 26 August 2016 (2016-kykt-08) and the latest amendment was approved on 26 October 2016. It was approved by the research ethics committee of Shanghai Changzheng Hospital affiliated to the Second Military Medical University on 22 November 2017 (2017SL051). It was approved by the ethics committee of Shanghai Municipal Hospital affiliated to Shanghai University of TCM on 22 November 2016 (2016SHL-KYYS-35). All changes are included in this protocol.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional files

Additional file 1:

SPIRIT 2013 checklist. Recommended items to address in a clinical trial protocol and related documents. (PDF 127 kb)

Additional file 2:

Model consent form given to participants and authorized surrogates. (ZIP 39 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • Yinang formulation
  • Efficacy
  • Safety
  • Autosomal dominant polycystic kidney disease
  • Stages III–IV chronic kidney disease
  • Randomized controlled trial


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.